Literature DB >> 1532638

[Pharyngeal and bronchial endoscopic study in the diagnosis and treatment of sleep apnea syndrome].

P Guérin1, L Lesenecal.   

Abstract

Obstructive sleep apnoea syndrome (OSAS) is a frequent and severe condition due to repeated obstruction of the upper airways during sleep. Sixty-five patients (57 men, 8 women) with clinical sleep apnoea syndrome were explored by pharyngeal endoscopy during wakefulness and during sleep induced by propofol, this anaesthetic agent enabling the patient to retain automatic respiratory movements. Nocturnal polygraphy was positive (apnoea-hypopnoea index greater than 10) in 60 patients (53 men, 7 women) and negative (less than 10) in 5 patients. The terms narrowing and obstruction were defined from our description of the pharyngeal cavity as seen at endoscopy. Endoscopic exploration during wakefulness displayed 4 pharyngeal lesions (2 cancers and 2 benign tumours) which were not responsible for the patients' OSAS. Forty-eight patients had narrowing of the pharynx (oropharynx in 45, nasopharynx in 3). Endoscopic exploration during sleep revealed inspiratory obstruction of the pharynx in 43 patients and inspiratory bronchial collapse in 1 patient. This study shows that the endoscopic findings can predict the efficacy of continuous positive pressure respiration in 97.3 percent of patients with obstruction of the oro and hypopharynx. The efficacy of uvulo-palato-pharyngoplasty in patients with obstructed oropharynx is questioned. The value of maxillary and/or mandibular surgical protrusion is discussed.

Entities:  

Mesh:

Year:  1992        PMID: 1532638

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  1 in total

1.  Identification of obstructive sites and patterns in obstructive sleep apnoea syndrome by sleep endoscopy in 614 patients.

Authors:  F Salamanca; F Costantini; A Bianchi; T Amaina; E Colombo; F Zibordi
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-08       Impact factor: 2.124

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.